医学
活检
滤泡性淋巴瘤
疾病监测
内科学
淋巴瘤
病理
疾病
放射科
作者
Ana Jiménez Ubieto,María Poza,Alejandro Martín-Muñoz,Yanira Ruiz‐Heredia,Sara Dorado,Gloria Figaredo,Juan Manuel Rosa-Rosa,Antonia Rodríguez,Carmen Bárcena,Laura Parrilla Navamuel,Jaime Carrillo,Ricardo Sánchez,Laura Rufián,Alexandra Juárez,Margarita Rodriguez,Chongwu Wang,Paula de Toledo,Carlos Grande,Manuela Mollejo,Luis-Felipe Casado
出处
期刊:Leukemia
[Springer Nature]
日期:2023-01-03
卷期号:37 (3): 659-669
被引量:24
标识
DOI:10.1038/s41375-022-01803-x
摘要
In the present study, we screened 84 Follicular Lymphoma patients for somatic mutations suitable as liquid biopsy MRD biomarkers using a targeted next-generation sequencing (NGS) panel. We found trackable mutations in 95% of the lymph node samples and 80% of the liquid biopsy baseline samples. Then, we used an ultra-deep sequencing approach with 2 · 10−4 sensitivity (LiqBio-MRD) to track those mutations on 151 follow-up liquid biopsy samples from 54 treated patients. Positive LiqBio-MRD at first-line therapy correlated with a higher risk of progression both at the interim evaluation (HRINT 11.0, 95% CI 2.10–57.7, p = 0.005) and at the end of treatment (HREOT, HR 19.1, 95% CI 4.10–89.4, p < 0.001). Similar results were observed by PET/CT Deauville score, with a median PFS of 19 months vs. NR (p < 0.001) at the interim and 13 months vs. NR (p < 0.001) at EOT. LiqBio-MRD and PET/CT combined identified the patients that progressed in less than two years with 88% sensitivity and 100% specificity. Our results demonstrate that LiqBio-MRD is a robust and non-invasive approach, complementary to metabolic imaging, for identifying FL patients at high risk of failure during the treatment and should be considered in future response-adapted clinical trials.
科研通智能强力驱动
Strongly Powered by AbleSci AI